Mozobil + Mozobil + Mozobil
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Beta-Thalassemia
Conditions
Beta-Thalassemia
Trial Timeline
Oct 1, 2010 → Dec 1, 2014
NCT ID
NCT01206075About Mozobil + Mozobil + Mozobil
Mozobil + Mozobil + Mozobil is a pre-clinical stage product being developed by Sanofi for Beta-Thalassemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01206075. Target conditions include Beta-Thalassemia.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01206075 | Pre-clinical | Completed |
Competing Products
18 competing products in Beta-Thalassemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ACE-536 | Merck | Phase 2 | 52 |
| Deferasirox | Novartis | Approved | 85 |
| Zoledronic acid + Placebo | Novartis | Phase 2/3 | 65 |
| deferasirox | Novartis | Phase 3 | 77 |
| ICL670 + deferoxamine | Novartis | Phase 3 | 77 |
| Deferasirox | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Phase 2 | 52 |
| ICL670 | Novartis | Approved | 85 |
| Bitopertin | Roche | Phase 2 | 52 |
| Luspatercept + Placebo | Bristol Myers Squibb | Phase 2 | 51 |
| CTX001 | Vertex Pharmaceuticals | Phase 3 | 76 |
| CTX001 | Vertex Pharmaceuticals | Phase 3 | 76 |
| CTX001 | Vertex Pharmaceuticals | Phase 2/3 | 64 |
| CTX001 | Vertex Pharmaceuticals | Phase 3 | 76 |
| Deferitrin (GT56-252) + desferoxamine (DFO) | Sanofi | Phase 1/2 | 40 |
| REGN7999 + Placebo | Regeneron Pharmaceuticals | Phase 2 | 51 |
| VIT-2763 60 mg QD + VIT-2763 60 mg BID + VIT-2763 120 mg BID + Placebo | LabCorp | Phase 2 | 49 |
| VIT-2763 once a day (QD) + VIT-2763 twice a day (BID) + Placebo | LabCorp | Phase 2 | 49 |